Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin. Kengo A, Nabisere R, Gausi K, Musaazi J, et al. Antimicrob Agents Chemother 2023 Oct 18:e0043023. doi: 10.1128/aac.00430.

Read + Share

Amedeo Smart

Independent Medical Education

Kengo A, Nabisere R, Gausi K, Musaazi J, et al. Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin. Antimicrob Agents Chemother 2023 Oct 18:e0043023. doi: 10.1128/aac.00430.
PMID: 37850738